mnopY;O89:;K$^_`aHPubMed%&I
!=ܠj89:;K@ABC89:;K<=>?O$^_`aj)
!"#$%&'()
#1%&3Pubmed
%eŒ3vitamin KOwarfarin
%&•Ž31988/1/1••H1‘’%&32008/2/652‘’%&32009/11/5b“”I
•73–Œ—˜UV5human5Clinical trial5Meta-analysis5Randomized controlled trial5Case
reports
%&V™#1š›589:;Kœ•žŸ< >?¡DE>?OmnopY;O$^_`aŸ< ‡ˆ$#1Ÿ¢
£%&¤¥OV™¦£b5§¢£%&¤¥$¨©#1buVzª«¬U•7H89:;Kœ•žŸ< >?¡D
E>?OmnopY;O$^_`aŸ< I-‡ˆŸ®¯V5°±RA"#Ÿ²£%&¤¥OV™¦
!"#$*+)
mnopY;O89:;K$^_`abcRA#1H¢£³´²£%&¤¥IŸ5§µ’b¶B*+V™¦
LM·¸¹;5stº4H»¼5†¯5½F5¾¿t25ÀÁs5…aÂ$=ÃI5ÂÄÅÆÇÈgj9OVz
international normalized ratioHINRIÉ5…aV™>?H89:;KIOÂÊHmnopY;I$FG5Ë̃
OËÌÍÎ5ÏЕŽ5Ñ;ÒÓ¹;ÔÕš´Ö`a$×Ø(5xUÙÚÔÛÜœÍÝ5Þt$ßg;Ô5."5
àjmjÒ5…abšA=‹†5Abstractor$ßg;Ô¦
!,-./)
0#123284546723447
!89:;K<=>?5@ABCDE>?$FG)
No.
>?ç
4672H#12I
1
‰Š
137H24I
2
òóHôížõö5÷øùßYj5àúûü5ý9þ5Û÷5ÛÈÿ!5½¨5ÛYoÈmj5"
Yj;#jþ5Wý$;I
117H84I
3
%&DEéHOsmolite, Ensure, Ensure® Plus, Isocal, Nutrilite 330I
77H74I
4
89:;K<=Xnè89:;é
47H24I
5
WøýÈ
27H24I
6
•$'$>?3Ù(W()Y5*+5,-9.ß5)h/ijþ
47H44I
7
áâ$>f$ãäHSTLMš›I
37H34I
Nîï46Cï2ðb
17O2ñ™¦
!JKLM$FG)
No.
JKLM$FG
4672H#12I
1
·j9012LM
UV
2
åæLM
47H44I
N14CNo. 3OPQRA
3
STLM
47H44I
N14CNo. 2OPQRA
4
îï4653jþÿYj4
367H214I
!¨©¤¥Hêt$…abšA=‹†$^_`a•ë$‡ˆ-5cì$=›•íU#1I)
No.
1
2
3
4
5
‡ˆ
4672H#12I
‰Š$dw'(
89:;K$|}~byBz
•€•UINRbuRA‚aƒ89:;K$D}„/H…a$=„†I
17H14I
17H14I
37H34I
17H14I
WXY;Z[\]O89:;K1O$^_`abcRA#1deO5>fghij$kl
mnopY;qar$stbuRA5>f$vwHxb89:;KIbyBz$,{
17H14I
\]^_`;a89:;K$bcdeHfgh%&I
!=ijk89:;K@ABC89:;K<=>?a$bcdek)
!"#$%&'()
#1%&3flgmnh
%op3vitamin Kawarfarin
%&qr31983stuH2009/5/26v%&wxI
y73z{5|}~•€•
%&S‚#1ƒ„589:;K…†‡•<ˆ>?‰DE>?a\]^_`;a$bcde•<ˆŠ‹$#1•Œ
•%&Ž•aS‚••v5‘Œ•%&Ž•$’“#1vNS”•–—Ry7H89:;K…†‡•<ˆ>?‰D
E>?a\]^_`;a$bcde•<ˆI˜Š‹•™šS5›œ•A"#•ž•%&Ž•aS‚•
!"#$*+)
\]^_`;a89:;K$bcdevŸ•A#1HŒ• ¡ž•%&Ž•I•5‘¢£v¤B*+S‚•
VW¥¦§;5¨©ª4Hs«5jš5MF5¬Q©25-®¨5¯e°$=±I5°²l³´µ¶k9aS”
international normalized ratioHINRI·5¯eS‚>?H89:;KIa°¸H\]^_`;I$FG5¹º»
a¹º¼½5¾¿qr5À;Á§;{áÄde$ÅÆ(5ÇRÈÉ{ÊË…¼Ì5Í©$ζ;{5."5
Ïk\kÁ5¯evƒA=ij5Abstractor$ζ;{•
!,-./)
0#123104546723 167
!89:;K<=>?5@ABCDE>?$FG)
No.
>?ô
4672H#12I
1
þÿDEáHVK¼!þÿá5^]Ê`è"®5÷]9:;®5#§;µ§;®I
87(44I
2
ùúHûüèÎ`k5ú$ýI
27H14I
3
"ü$µ
27H24I
4
õö
17H14I
JKLMNOPQ
5
89:;K<=÷]ø89:;á
RS
6
†$%$>?3Kì>?H&&ü;aÈ]Êü;I5ùú'(kÛ5)*+,
37H34I
JÔÕ46CÕ2Öv
17a2Ó‚•
!TUVW$FG)
No.
TUVW$FG
4672H#12I
1
¥k9×ØÙVW
RS
2
XYVW
27H14I
3
Z[VW
RS
4
ÔÕ465ÚkÛÜ`kÝ
147H94I
!’“Ž•Hð©$¯evƒA=ij$bcdetñ$Š‹˜5Ÿò$=„†óR#1I)
No.
1
2
3
4
Š‹
4672H#12I
§;9kçè{éê뇔BAKì>?a\]^_`;a$bcde$íîjvŸ•Aïo
\k^_`;Þe¨©vÃßA89:;K<=àá$¹ºâã
äåà?g$89:;K$æ\]^_`;Ê`ÉË$°ÐvÑÒ•ºÓA89:;K¾¿»
17H14I
17H14I
17H14I
17H14I
UVWXY3Q0123K>pqr[A'¡>¾¿$%B
!5no”0123K89:;0123K4567Q>pqr[”&
!"#$%&
'()*+38,-,./*+60/
!0123K4567-89:;<=67>?@&
No.
1
67â
,./*A()*B
ñò<=ÌAOsmolite, Ensure, Ensure® Plus, Isocal, Nutrilite 330-VKóôñò
Ì-WV•YÂœ®-•V123®-ëÀ3«À3®B
15/A11,B
2
Þß
14/A3,B
CDE-1/;FG
HIJKL
3
¸¹AäDÇåæ-ç©ÂµY”-èéêë-ª1™-•ç-•«šì-Hg-•YW«U”-í
Y”3î”™-œªï3-¹>ðB
13/A9,B
4
œ©ª«
4/A4,B
5
0123K45•Vã0123ÌAÓt>,.>³B
4/A2,B
6
{>¬>67+-®œ®¯Y-°±-²³1´µ-¯¥¶¦”™-F·67A®®©3Q-V•
7/A7,B
©3B-¸¹¶¦”™-º»¼½
7
ÐG>6`>†‡AÑÒOPmz-Ót>,.>³B
3/A3,B
CŽ•,.;•*•_
1/Q*Š‘’
!MNOP>?@&
No.
MNOP>?@
,./*A()*B
1
“”1•–—OP
|Ö
2
ÔÕOP
6/A5,B
C1,;No. 3QRST9
3
ÑÒOP
4/A4,B
C1,;No. 2QRST9
4
Ž•,.-˜”™šY”›
50/A30,B
!ghijAk^>l[_m95no>pqr[st>uvw-xy>5z{D|()B&
No.
1
2
3
4
5
6
7
8
9
uv
,./*A()*B
1/A1,B
1/A1,B
3/A3,B
œ•Y3žŸ ¡Q0123K1Q>pqr[_xT9()¢£Q-6`¤¥¦”>§¨
1/A1,B
UVWXY3Z[\>]^_IT9-6`>abAc_0123KB_d:e>"f
1/A1,B
À31”ÁÂÃÄÅÆÇe:9F·67QUVWXY3Q>pqr[>ÈÉo_xT9¢£ 1/A1,B
U”WXY3Z[]^_ÊË90123K45•Ì>͉ÎÏ
1/A1,B
}~•7\>0123K>€#
1/A1,B
UVWXY3•Y‚ƒ>„…_†‡ˆ‰Š90123K‹Œ•
1/A1,B
Þß>¢bàá
0123K>×ØÙ_d:e
ÚÛÜ|INR_IT9Ý[•0123K><Ø…%Al[>5…oB
>?@AB5n2345K:•Ž•G
U•:3‘’?B“’”•–—˜2345Kr/™m2345Kš•)*n:•Ž•G›
?@Aý:U•No.mNæçÊËB-ônIHÒ:No.-•C{/˜DE:FG~2: HIJKN3: LúJKN4: œ•žŸNMa“NBaO›•
1. !"˜PubMed”2žN]1¾”1ž›
1.1
!"#$%&'()'*
!"
!+,-./0*
1) œ•žŸ˜3œ•N>?@AB5 Gjk›
2) !"+,ÊË-1˜1¦ND§¦›
3) !"+,ÊË-2˜7¦ND§¦›
!51*
¦Z¯°±²³-e67fgx´µt™/jk~!":+,-.¶’&5¡¢“’£˜TT£›~·¸¹Hœ•:žŸnNº:•Ž•G-»
™t¤¥x¼oH•
ZX[\Nýþÿ!N"QR\N#$%&N'()N*+D,N-./0
e67fg1:!"-./>a@AB5Ïe•G
]1:r234104 : 36-38, 1978
Pubmed 56E¹
!":+,qN+,†‡N€•-7¦8Eؤ¥x}{/âãm9€×t™/~Ne67fg1:jk-nstN!"m:ü¹™B“%@A
%3alr¶N);êë-å{/<=~|}lr/n>ü×/•
!"#$%&'()'*
!"
!+,-./0*
1) œ•žŸ˜10œ•N>?@AB5 Gjk›
2) !"+,-./’&5¡¢“’£˜TT£›9:;<:¤¥˜1¦ND§¦›
3) 0¨12345K'©?:ª«˜10¦N¬-®D§k›
!1234*
(4.10)
!1267*
!PMID*
1.2
!PMID*
¦Z¯°±²³-e67fgx´µt™/jk~!":+,-.¶’&5¡¢“’£˜TT£›~·¸¹Hœ•:žŸnNº:•Ž•G-»
™t¤¥x¼oH•
Kudo T.
Warfarin antagonism of natto and increase in serum vitamin K by intake of natto.
Artery. 1990;17(4):189-201
2360879
!51*
!":+)-.¶0¨12345K'©?:À¼{/„n…•Ne67Áf1:jkmÂq:!":+)xyz{/„nxÃÄ{/•
!"#$%&'()'*
!"N%&'(
!+,-./0*
‚§¦xÅÆn¹Hpq:!"Ç.$%&'(:ÈÉ+,Ê˘%&“ÌaÍagN13¦›
!1234*
2345KxÂq-šÎ)*mN>?@AB5-ŹÏeÐ-•G¹Nº:ÑÒÐ)*lr/!"m67®-ÓÔx#Õ{„n~Ö•×t™
/•¹…¹N+,q-»™tØ:ÙÚ:yzx{/ÛÜ…n™ÝÞßmEàNá§: ^FG·:âãnEst™/•äåNæçèé-ǵ
/>?@AB5 Gjk-Å{/ ^êëlmNì!"míÅ-)ÛE™lJ€™înêë{/ku™×ïNì!"m)ÛðñE™lJ€™î
nêë{/kuǶNº:òóm«ôst™E™•º„lNõÉmN‚§¦-pq:!"x+,€öN2345K01÷ÚEØ:ÓÔxøÛ/
„n-.¶N‡ùÐ-lmr/~N>?@AB5 Gjk:!"+,:âã-»™tŠúx¼o/„n-¹H•ôHN2345KxÂàšÎnû
ü×t™/%&'()*:+,-»™tu¤¥¹H•
!1267*
!"#$%&'()*+,-./012345K#$6789:;<=>?@AB5:CDEFG:HIJKLMNOPQRNSTUVNWXYNZX[\
]^_`ab?=33c10d Page2559-2564(1997.10)
!1234*
(4.11)
!1267*
1.3
(2.5)
½]1¾¿
!PMID*
!51*
>?@AB5-./e67fghi1:jklmNHnopq:!"lrstuNvw-+,xyz{/|}~r/•€•-N%&'()*
uN‚ƒ)*lr/„n…•T†‡+,xˆ‰{/„nxŠ‹{/nN+,xŒo/|}~r/•
2. ”•zPubMedé8•'^d.é1•{
2.1
(2.1)
!"#$%&'()'*
!"#$%&'Á}ªÂÃ';Ê3'0123KÎÏzKonakion®{
!+,-./0*
!1234*
z/0çè{
;<=>%3õ_8—no'0123KG¬-812+3¯z!"#$%&'Á}ªÂÃ{4;Ê3/67/ñòGóôh•]
Karlson B, Leijd B, Hellström K
On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.
Acta Med Scand. 1986;220(4):347-50.
3541503
@vwõ_d'0123K•¬-O+¯z250 µg&'{/67B'$'N•ª()*OnùÔhªOn•'Ûsho67K:§+ñòG,
-K›œA••:]
!1267*
!PMID*
!51*
!"#$%&'()'*
2.2
(2.2)
!+,-./0*
!1234*
!1267*
!PMID*
!51*
!"#$%&'()'*
!+,-./0*
2.3
!1234*
(2.3)
!1267*
!PMID*
!51*
!"#$%&'()'*
!+,-./0*
2.3
!1234*
(3.2)
2.4
(4.6)
¡¢/+,«0123K/¬-O11®/+¯z!"#$%'°%=±;&'²³')*&'´µ¶·'¸%&3¹&k')1k'º»)3¼»'l)
¼3'½´µ¶·'¾/¿”•À
1) åæZçèéêëSC"D$<zObservational protocol{
2) ìæZçèéíÜîl"kÒ&*&C"D$<zRandomized crossover protocol{
+,-./0123K67§@vwõ_/öïðA8mno/Š÷AGø|ù8K:“SN'
Franco V, Polanczyk CA, Clausell N, Rohde LE.
åæZ—9úìæZçèGûüh•]
‘’“SN”•d–/+,
!51*
z;<=>%3?@A/7%8mno/óô{
;<=>%3?@AGtXh•fa8gh'Õ/7%Gø|ù8K:•8';<=>%3/ÿ9•yG:~';<=>%3?@A8gK:r0
123K+/67/ñò8mnoóôh•]
Qureshi GD, Reinders TP, Swint JJ, Slate MB.
Acquired warfarin resistance and weight-reducing diet.
Arch Intern Med. 1981 Mar;141(4):507-9.
7212893
‘’“SN”•d–/+,G67hon:fa8—noB'+,-./0123K67’/˜™8stK:šgSO;<=>%3?@AG
YZ[\K›œA••:]
!"#$%&'()'*
!"#$%&
!+,-./0*
X€•‚zCase reports'2X€{
!1234*
žŸ
!1234*
!1267*
'fa/¡¢/+ˆ£z!"#$%&/¤’67{G¥¦h•\§89‡';<=>%3¨A•YZ[\©ª•X€/•‚N•:]
!PMID*
Kempin SJ.
Warfarin resistance caused by broccoli.
N Engl J Med. 1983 May 19;308(20):1229-30
6843604
!51*
;<=>%3¨A•;8|ª:faB'<8=>/+,?z!"#$%&@/ˆ”•GAB867honOnù{8CDK~ZN•:]
!"#$%&'()'*
¿”•/N±Oz)1k'°!'°±PÑ'!"#$%&{
!+,-./0*
X€•‚zCase reports'1X€{
!1234*
‘’“SN¿”•d–/+,EFG/jJ•;<=>%3õ_/?@AGYZ[\h'TUOQRSHIz–JKL{GMn•X€•‚
N•:]
!1267*
!1267*
!51*
2.7
Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and
randomized protocols.
Am J Med. 2004 May 15;116(10):651-6
15121490
0123K67’/jJB'ýþ@vwõ_ÿGbchon:fa/INRGj•©!:"#O$%N•:]
!+,-./0*
!PMID*
(4.12)
åæZ—9úìæZçèGûüh•]
!"#$%&'()'*
2.6
(4.7)
1) åæZçèéêëSC"D$<zObservational protocol{
2) ìæZçèéíÜîl"kÒ&*&C"D$<zRandomized crossover protocol{
+,-./0123K67§@vwõ_/öïðA8mno/Š÷AGø|ù8K:“SN'
Franco V, Polanczyk CA, Clausell N, Rohde LE.
!PMID*
!51*
!PMID*
2.5
0123K•¬-O+¯'0123K•56h•+¯
Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and
randomized protocols.
Am J Med. 2004 May 15;116(10):651-6
15121490
0123K67’/jJB'ýþ@vwõ_ÿGbchon:fa/INRGj•©!:"#O$%N•:]
!1267*
(4.5)
0123K/¬-O”•zÁ}ªÂÃ'!"#$%&'Ä´µ¶·')1k{
012K/Åhn”•zDÆD'´Ç»%'ȵÉÊË'1ÆÌÍ{
0123KÎÏz=ÐDÑÈÒ3{
íÜîçèzRandomized study{
;<=>%389:@vwxy/ïðA8gK:'0123K•¬-•:nBÅhn”•/67/ñòGóôh•]
Pedersen FM, Hamberg O, Hess K, Ovesen L.
The effect of dietary vitamin K on warfarin-induced anticoagulation.
J Intern Med. 1991 Jun;229(6):517-20
2045759
1ÓNÔ+,-./0123K67’•—9Õ1000 µg˜™K:§'Ö×vw£A/ØÙhPOn˜™GÚÓFYZ[\K]Ù•'Ûsho
67K:\§89‡\/ÜcBÝ™h'¡¢/+,G¥¦hoÔÚÓFBÞß•sP\§•àᩪ•]+,-./0123K67/Óâ/
j•B250-500 µgGãäOn9}8K~ZN•:]
Walker FB 4th.
Myocardial infarction after diet-induced warfarin resistance.
Ann Intern Med. 1984 Oct;144(10):2089-90.
6486994
+,-./0123K/456789:;<=>%3?@AB'C"D"303EFGHIJK:LMNOP'QRS8TUOVWXGYZ[
\K]^_`,aB';<=>%3bcd/efa8gh'+,-./0123K67/ij/%kl8mnopqh'r0123K+8st
K:”u@vwxyzunderanticoagulation{”8O|On9}8K~ZN•:]
!"#$%&'()'*
!"#$%&'()*&
!+,-./0*
!1234*
X€•‚zCase reports'2X€{
+ƒ„/…ZOj†89‡'ˆ‰8Š‹:VWXGŒ}@vwxy/j•GˆŽ•2•/fa/X€N•:]
Chow WH, Chow TC, Tse TM, Tai YT, Lee WT.
Anticoagulation instability with life-threatening complication after dietary modification.
Postgrad Med J. 1990 Oct;66(780):855-7
2099431
QR8‹•:ýþ@vwÿbcfa•+,EFGj†K:SV'0123K67’GT"8óôh'Õ/IU§hoˆŽ:jJGCDTP
VWK:X#••:]Ù•'@vwxy•ïðK:ÙNINRGAY8ËZ1&K~ZN•:]©|8'ˆ‰8Š‹:9}OVWXG[\K:
•8'+,EF/…]Oj†z<80123KG¬-8129}O+¯{B^M:9}8K:]
!1267*
!PMID*
!51*
2.8
(4.17)
2.9
!"#$%&'()'*
•Ž
!+,-./0*
!1234*
!PMID*
!51*
&'234Case reports.1&'5-letter’–6789,:;<#0=>Q—˜™.@AB:KCFG•Ž0•hJK#‘Q’–.†‡?šP›•O&'023UVWX
Beanland DR, Dorsey DA.
Monitoring warfarin therapy.
Am Fam Physician. 1999 Sep 1;60(3):764, 766
10498107
†‡0ˆ‰y.@AB:K0Š‹ŒghW•Ž0zIJK0••h#‘Q’Wg“”•WX
!"#$%&'()'*
&'1) ()*+,-.&'2) /01
!+,-./0*
!1234*
&'2342&'5
6789,:;<=>?.@AB:KCDEFGH/0DIJKCLMNOOPQ.6789,:R<?STNO&'23UVWX
YZ[\UP NST&']^ _`-Z[abcR<d_`-Z[abcR<?efghiO4'
jDkl
mnZ[dopZ[\UP NST&'] Page141-144(2008.08)
!1267*
(4.22)
!"#$% !1267*
!PMID*
!51*
6789,:q;=>0rstuvwxh0y.@AB:Kz{JK0|}gg~Q.JKI0•€h•‚Cƒ„W…gUVWX
3. /0àá16PubMedÇ749"#$Ç447
3.1
(4.1)
3.2
(4.2)
!"#$%&'()'*
Osmolite
!+,-./0*
!1234*
!PMID*
23456Case reports91237-letterWT23I/0àá1OsmoliteN+š[^&'()KNWT9`abcd)4›½Yt$%A23RS^_
Lader E, Yang L, Clarke A.
Warfarin dosage and vitamin K in Osmolite.
Ann Intern Med. 1980 Aug;93(2):373-4.
7406391
!51*
"|&Ìg89/0àá1'&'()K1IþýÿRST9`abcd)NW^›œ••|=()x^*+–tS^rŒ=õ,xÅÆRS^_
!1267*
!"#$%&'()'*
Ensure
!+,-./0*
!1234*
23456Case reports91237-letterWT-./0RJK=ÈÉ@A/0Ý1òºI&'()KàýNWT9›œ•ÀIø›–=12@A23RS^_
O'Reilly RA, Rytand DA.
"Resistance" to warfarin due to unrecognized vitamin K supplementation.
N Engl J Med. 1980 Jul 17;303(3):160-1.
7383081
‘DIúû/0Ý18”ü[A”&'()KàýIþýÿRST9-ö›œ•ÀN÷@®¨–I!"lø›–=ùƾrx_
!1267*
!PMID*
!51*
3.3
(4.3)
3.4
(4.4)
3.5
(4.8)
3.6
(4.9)
!"#$%&'()'*
Ensure Plus
!+,-./0*
!1234*
23456Case reports91237
‘sI&'()K=+,x^/0àáËâEnsure PlusIJKNWT9`abcd)#–t$%A23RS^_
Michaelson R, Kempin SJ, Navia B, Gold JW.
!1267*
Inhibition of the hypoprothrombinemic effect of warfarin (Coumadin) by Ensure Plus, a dietary supplement.
Clin Bull. 1980;10(4):171-2.
!PMID*
7214706
!51*
/05Î8tBfgNh]\@6@6ÛÜŒpT9/0àá187ûlp89Nh]\æ·p:;=<¿_@ò@9r[ºIfg8=>“
?2@“?A?2I12Bt*]A§9`abcd)IW¿p›œ•ÀeYfg=•|x^"C89DEp/0àá1I/0FG6H17
Œ¾rTI^J½Y=õ,xÅÆRS^_
!"#$%&'()'*
Ensure
!+,-./0*
!1234*
!PMID*
!51*
23456Case reports91237-letterWTúû/0Ý1#Iõ,Z[\]p]&'()KàýNWT9`abcd)ø›–t$%A23RS^_
Lee M, Schwartz RN, Sharifi R.
Warfarin resistance and vitamin K.
Ann Intern Med. 1981 Jan;94(1):140-1.
7447217
`abcd)ì)Ø×Matíîpï?Nðñ@Aº9&'()K+,Ëâ=JK@\]p]òó¿ò9ôõxÅÆRS^_
!"#$%&'()'*
Isocal
!+,-./0*
!1234*
!PMID*
23456Case reports91237
&'()K=‘D+è-./01NWT9-ö›œ•ÀN÷@ø›–=ùƾr@A23RS^_
Watson AJ, Pegg M, Green JR.
Enteral feeds may antagonise warfarin.
Br Med J (Clin Res Ed). 1984 Feb 18;288(6416):557.
6421377
!51*
-ö›œ•ÀeYfgt-./01JK=ÈÉS^]8#0x^ŒÆ89Ö×Ø×)&)K=LMNNÚx^rŒt¶·RS^_ON9f
gt-./01òºPQËNR^£89dSTtUVx^*+–tST9WºX¤N¨©p›œ•YZNp^ò'@[p]_
!1267*
!1267*
!"#$%&'()'*
Nutrilite 330
!+,-./0*
!1234*
23456Case reports91237
[s\lR/0àáËâ=XY@A]^_`ØËÌ|}IÈÉNWT9Ö×Ø×)&)£¤IÒÓt$%A23RS^_
Oren B, Shvartzman P.
Unsuspected source of vitamin K in patients treated with anticoagulants: a case report.
Fam Pract. 1989 Jun;6(2):151-2
2663579
!1267*
!PMID*
!51*
3.7
(4.15)
G23WT9`abcd)Œ»¼½Y=¾r@¿^ÀÁIJKNk@9ÂIW¿pÃ5=ÄYxÅÆRS^Ç
1. ›œ•À•|=ÈÉx^ÊN9ËÌÍ=ÎÏx^_
2. ›œ••|#Ifg89ËÌÐÑIÒÓ=45x^W¿ÔÕx^_
3. Ö×Ø×)&)£¤IÙÚ–NÛÜtS^fg89ËÌÐÑIÒÓN{]\ÎÏx^_
4. ÝÞßg89/0àáËâ#I&'()K+s=45x^_
!"#$%&'()'*
Ensure Liquid
!+,-./0*
!1234*
23456Case reports91237_ã&'()KŒ`abcd)I»¼½YNh]\9”, –IÐÑIä唌æçx^_
&'()K=+è/0àá1IéÚêpJKNWT9INRtÒë@A23RS^623-37_
Brigden ML.
When bleeding complicates oral anticoagulant therapy. How to anticipate, investigate, and treat.
Postgrad Med. 1995 Sep;98(3):153-4, 159-62, 164-5
7675740
&'()KIJKs=,«NÒÓZ™^ËÌIÒaN89bcIª«=d¿ÅÆRS^_ONINRt•|eÐNSf\'UVlNæ˜pg
ÒNðñx^*+–tS^IR9“h@i.’“I,j8QNŠ‹xÅÆRS^_šA9’“tpDINRIklpmnIŒÆ8opT9q
1p’“tS^fgN÷@\8&'()KIij@rIÀÁstt¶·Np^ò'@[p]_
!1267*
!PMID*
!51*
!"#$%&'()'*
&'()K*+,-./01
!+,-./0*
234562237
!1234*
&'()K*+,-./016VK-./01789:;<=>?@9ABCDE=FGHIJKL'M)NOPQA-./01RST9UV
R8WDXYZ[\]^_`abcd)eYfgNhQ^-./01IijNk@\UVlNmn@A458op]_qrR9&'()KJK
stPT-INR6prothrombin time-international noralized ratio7uvwxyzN{]\mn@A_
3.8
(4.23)
!"#$% !1267*
&'()K*+,-./01I`abcd)|}Nvwxyz
~•€•9‚ƒ„…9†‡ˆ‰
/0-Š‹Œ•|Ž25•6• Page481-484(2008.12)
!PMID*
!51*
‘sI`abcd)Iij8’“I”•–=—˜Z™^_šA9VKNW^›œ•žŸ ¡8¢£¤¥¦x^A§9`abcd)=—sZ™
^VKI¨©JKN8ª«@9`abcd)ij£IVK-./01I¬Y8-®¯°Œ@\8±Q9`abcd)ij£N8PT-INRhW
²VKJKs=ª«³D´µx^rŒt¶·Œ¸¹º[A_
!"#$%&'()'*
]ïðñbcò‚ó…†&C·#"Y%kô®¸
!+,-./0*
VWµ¶·3VW¸
!1234*
3.9
(4.24)
!1267*
vw]xy
õö÷ø6!"#$%&šA^_6¥ù4ò‚ó…†&C‡ˆ~YL%M•€RS)#"Y%kô®/@AHu3VW'¿pd4#"Y%kô®
\;ú½6!"#$%&AÇNû€+,I6üý/þÿHuT
#"Y%kô®N!"#$%&O@Aƒtu¡!34~YL%M•€«¬"6w#6˜$%&N4'"4BC(R#"Y%kô®þC"'®š
\B°/)˜Hdpoq¤u5NO|}Nr<st)T
!"#$%&Y%Z[N]ïðñbcò‚ó…†&C6*+,A
-.™4á/0142345467849:;4</=>4?/;@
AU÷øBC#BCxì43í7î Page907-911(2007.07)
!PMID*
!51*
!"#$%&šA^_Oò‚ó…†&C‡ˆ~YL%M•€RS)#"Y%kô®/@A2)N4?D!"#$%&\;Ç3E2Fˆ¨'ÆG
H4KL&H‹IKJ6üKL316%M¤uTN¤d4!"#$%&šA^_']ïðñbc/1±Hò‚ó…†&C/\;2)O‚4ó…†
&KP‡ˆò‚ó…†&C6QROSQRS)THqH4ó…†&KP‡ˆò‚ó…†&C6TUVA34ó…†&KWXVNo)YIÓOS
)TZ[\C6ó…†&K‡Ç3100 µg/A]õN^_ƒtdp)6R4Z[\C6@A'(X4û€+,I`69:/zab'HoOs
ó…†&K6cdOYINr<st)T
!"#$%&'()'*
~YL%M•€'•‚ƒtuò‚ó…†&C·„"…†&®¸
!+,-./0*
VWµ¶·1VW¸
!1234*
3.10
(4.25) !1267*
vw]xy
!PMID*
eaVfg^_'-H!"#$%&O\;ƒtuO4~YL%M•€'•‚ƒtu„"…†&®'‡ˆƒtdpu‰Š‹KŒ•&6\;NŽ6
]•'(X4INR6J&KLM"O%ã'o¤uVWRS)Thu4UVW6^_'3˜™VOSX4šB›œO•žouŸ4BC ¡›
œ¢£O01ƒtdpoq¤uT
šB›œ•ž^_`6Bij«¬kl6SQÓìeaVfg^_'¿À)!"#$%&J&KLM"6VWmn
o:pq4r/ps
AU÷øBC#BCxì41í7î Page863-866(2005.07)
!51*
UVW6!"#$%&J&KLM"'z{9:/;<u|}34~YL%M•€'•‚ƒtu„"…†&®'‡ˆƒtdp)‰Š‹KŒ•&6\
;NŽ6]•RSX4ƒs'4…&•&‘h"’†&/“”•–‘h"†•Z[{—sq69:/;<uNr<st)TUVW6^_3˜™V
OSXšB›œO•žouŸ4BC ¡›œ¢£O01ƒtdpoq¤uT!"#$%&6(¥o¦'§¨2©ªB>O«¬ƒtu^_'
-H4®šB?§¯C/‡ŸuB° ¡3PQRSX4šB›œ•žo^_'{±²t)©ªRS)T
!"#$%&'()'*
³–&´–&®
!+,-./0*
VWµ¶·2VW¸
!1234*
3.11
(4.26)
vw]xy !1267*
*+,-.]6P¹º»¼½½¾V^_'¿À)ÁÂbc
¡NHd³–&´–&®'()ÃÄqs6`
bc./01HuN5Å4!M
#$%&®/ÆÇHd{+,IÈÉ/ÊË2)5NOÌÍÎ4º»¼ÏÐ6ÑÒÓOÑÔƒt)ÕÖ'o¤u2VW'×pd6µ¶RS)T
!"#$%&Y%Z[78O³–&´–&®RØÙƒtu2W
ÚÛÜÝ4ÞßàƒÝ4áâãä4åæçè
bc-éêNë-ì17í2î Page291-295(2000.05)
!PMID*
!51*
!"#$%&'()*+,-./012)'345678'9:/;<)=>?@ABC'DE'FGH4+,I/J&KLM"2)5NO
PQRS)TUVW(X4!"#$%&Y%Z[\;]6^_6`abcCNHd34e&fgh®i%jklOmnR3opqNr<stuT
4. Þßà;K*+F7GÞßà;…e4t4225
!"#$%&'()'*
Þßà;K*+F7GÞßà;…
!+,-./0*
uv›wxòyzÖ×4Prospective open-label controlled trial5
!1234*
;ÆAÓ:Í=Þßà;K1>?=6789:;‰?Š‹@ƾCb;?Ò=Þßà;K1•*ðfg=F7GÞßà;…•–=[\•òóM
NR
Kurnik D, Loebstein R, Rabinovitz H, Austerweil N, Halkin H, Almog S.
4.1
(2.4)
!1267*
!PMID*
!51*
Over-the-counter vitamin K1-containing multivitamin supplements disrupt warfarin anticoagulation in vitamin K1depleted patients. A prospective, controlled trial.
Thromb Haemost. 2004 Nov;92(5):1018-24
15543329
Dc#;Þßà;K1(<7=•FG2Ÿ#Š‹—bfg=Þßà;K1*+F7GÞßà;…•–@AçINRŒ;÷MNR¿¶Açb¿=Š‹
—ÑÒ=Þßà;K1•–OPBC³Ah@BCMb•FG>?=iS“•jk@ܵŽ¿<ŒlmܶNR
!"#$%&'()'*
Þßà;K*+F7GÞßà;…
!+,-./0*
01234Case reports!3"#5bÞßà;K`a‹=æT
25 µg=Þßà;K1*+F7GÞßà;…••Íê@•–UVPQ¾—#WMNX0binternational normalized ratio 4INR5Œ2ŸY
!1234*
Z[PQ¾—Z÷@¨BN3Î=Š‹4=\2Η®]¨^>0•>_5@í¾C=23OPQRÞßà;K1`a0=+‚b4Dc#Þßà;
K1(<75=æT³dBNR
4.2
(4.19)
!1267*
!PMID*
!51*
Kurnik D, Lubetsky A, Loebstein R, Almog S, Halkin H.
Multivitamin supplements may affect warfarin anticoagulation in susceptible patients.
Ann Pharmacother. 2003 Nov;37(11):1603-6
14565795
7‹µ=&:89&@:ƒŽQŠ‹=12%—;Þßà;K1(<7¦BN=Ob¿=A=¨;Þßà;K1>?=Š‹—ÑÒ=Þßà;K1•–@
AQä@@ÏMC³INRŒ±A@BCŽQ<DEMC¾QR•FG2Ÿ#=Š‹—bÞßà;K*+F7GÞßà;…=•?•23MbHI
"—•FG2Ÿ•J§C¾QŠ‹@ƾCbK@INR=L,M¨¾ä@@MNMN<›b”=A=¨OP:Q;R=•?@í¾CS,ê@æ
TŽQš›OPQR
5. &'()4PubMede22b"#$e225
5.1
(4.13)
5.2
(4.14)
!"#$%&'()'*
&'()
!+,-./0*
!1234*
!PMID*
!51*
01234Case reports!1"#5-letterAç&'()•–UV@Açb6Ú89:;=•FGY?Œ•‘MN01OPQR
noop
&'()—6Ú89:;=•FGY?••‘ŽQ
•q‡$b82(2): 137 1993
Pubmed rs¨M
&'()—6789:;=•FGY?••‘ŽQ=O{|ŒÇÈOPQR
!"#$%&'()'*
&'()
!+,-./0*
!1234*
01234Case reports!1"#5
&'()•–UV@Açb6789:;}•Y?Œ~•N01OPQR
Ohkawa S, Yoneda Y, Ohsumi Y, Tabuchi M.
[Warfarin therapy and chlorella]
Rinsho Shinkeigaku. 1995 Jul;35(7):806-7
8777808
&'()—•–Ò<•–,èb-Î.•´LŽš›OPQŒb6789:;=/0••‘ÜÝQ1aOPQ’H“•*ðRÀÁb6789:
;2Ÿ#=Š‹OTT3@äåŒ4µ¶Q<›—b&'()=•–³56ŽQÇÈŒPQR
!1267*
!1267*
!PMID*
!51*
5.3
!"#$%&'()'*
ËÌb&'()
!+,-./0*
SÍΕÏÐ<MNÑÒ=ËÌÆAÓ&'()=ÔÕ•–Ö×4&'ØÙÚÛÚ b13Î5
SÍÎ@ÑÒ=ËÌ••–ÜÝbÞßà;KD#áâ¨ã=äå•æšQ¿<@Açbèéê@O—PQŒb6789:;‰?Š‹=ËÌ•
–=ëì@í¾C´î•ï™NRœNbÞßà;K•ª©*ð<ñʶC¾Q&'()UV=•–@í¾C³òóMNR
ËÌôÓ&'()UV•–@AQD#Þßà;KôÓFGõZ=[\ö6789:;=¹n¨•?=N·@
÷{øùbúy`ûbüýþÿb!"#b$"%&
"„'(Ú)7ö33*10+ Page2559-2564(1997.10)
!1234*
(2.5)
!"#$% !1267*
!PMID*
5.4
(4.27)
!"#$%
!51*
6789:;@AQ•FGŸ €d#=Š‹O—bN<™ÑÒ=ËÌOPBC³b•‚@•–•XƒŽQÇÈŒPQRܵ@b&'()UV
³bSTUVOPQ¿<„µý,è•–•…†ŽQ¿<•´LŽQ<b•–•˜™QÇÈŒPQR
!"#$%&'()'*
&'()*+,-./
!+,-./0*
!1234*
012341015
6789:;<&'()*+,-./<=>?@ABCDEFGHIJ@KLMN01=23OPQR
STUV=DEFGWXY?Z=[\
]^_`abcdefgbhijkblmnobpqrsbtuvwbxyzb{|}~•€
•q‚ƒ„…†‡ˆ$b40: p949-950b2004
!1267*
!PMID*
!51*
6789:;‰?Š‹Œ&'()*+,-./•>?ŽQ<b•FGY?=•‘ŽQ’H“ŒPQ=Ob”=•–—˜™Qš›OPQRœNb
STUV=•?Œ„žŸ ¡U¢Ÿ @[\•£™Q’H“—b¤¥Y?¦§O—¨©bSTUV=ª«¬•?@AQh-=®¯°£
¡±²•–³´™µ¶QN·bŠ‹Œ•?ŽQ¸@¹º¨»2¼½•MC¾©¿<ŒÀÁ=„…IJÂÃÄÅ@ƾCÇÈ<ÉʶQR
6.
žJ‰JËA.PubMed¬\A«A•4@–”@•‚£ƒ„@•€¾¿1À/@."#$¬¼½¾¿1À@AAà5M\Á]à5@
&'()/
!"#$%&'()'*
\A«A•4
!+,-./0*
*+,-.Case reports!1"#/
0Á234578#J=>?@-®J\A«A•46¥Õ‘96h=`KÓ9@international normalized ratio .INR/?äf9[=>
J*+\]<^
Bartle WR, Madorin P, Ferland G.
Seaweed, vitamin K, and warfarin.
Am J Health Syst Pharm. 2001 Dec 1;58(23):2300
11763808
!1234*
6.1
(4.18)
!1267*
!PMID*
6.2
(4.16)
6.3
(4.20)
6.4
(4.21)
!51*
\A«A•46¥Õ‘9ƉJËA‹¢£¤5K¥¦¶ËAJ4ÀD`¥Š<º»\]b@”êì‹å¯INRJ°;6.>Äš`/±²<î“
9êV;^9î9@¢£¤5KKÓ`a<äf?>Äš\]êë@0Á2345³´=Jäf6ܬM9V;XµÛ^
!"#$%&'()'*
–”
!+,-./0*
!1234*
*+,-.Case reports!1"#/
–”M0Á2345JK—˜8`5;:J*+\]<^
Taylor JR, Wilt VM.
Probable antagonism of warfarin by green tea.
Ann Pharmacother. 1999 Apr;33(4):426-8
10332534
!1267*
!PMID*
!51*
0Á2345‹…i`¦H¶Jc;Y†0‡ˆ®\]<?@‰J®1@ËAÆ+ŠMJK—˜8J´µ¶?]<[Š‹ŒV•€£45Ž
?ܬ\]<^¢£¤5K‹0Á2345J˜8`•0‘<”M?a¹Jìê:;<J\@¢£¤5KJ]•bJìê:;V;•‘’6Uìî`
‘<”M‹«¬\]<^“ê[F”\‹¢£¤5K=?•¹V<?@”J<1À\‹&=J–”J—8`ab@INR?˜™š`¦ÙVäf6
›”9[”M6œ•:;<^žêŸG@0Á234567®9:;<=>`35£¢¿1‘<M»‹@®Å ?—Ë1Jäf`5;:¡–š`
¢É‘<”M?£ðܬ\]<^
!"#$%&'()'*
•‚£ƒ„
!+,-./0*
!1234*
*+,-.Case reports!1"#/
h¹Jz†¤¥3¦5D§J]<=>`F;:@0Á2345¨©#`•‚£ƒ„6G89[M»J¦ª˜8`5;:J*+\]<^
Kuykendall JR, Houle MD, Rhodes RS.
Possible warfarin failure due to interaction with smokeless tobacco.
Ann Pharmacother. 2004 Apr;38(4):595-7
14766993
!1267*
!PMID*
!51*
¶Þ`I[<zNƒ„Æ·¸#§J]<=>J0Á2345¨©J¹ªJ+\]<^”J=>JºÖ»¥¼=J½¾`ð9@•‚£ƒ„
J¿–î5ÀÁ`G89[”MJÂËÄÅ\»V;^0Á234578#`•‚£ƒ„6G8‘<”M‹@h¹J=>`ð9ØÙ‘<ܬ
?]<^”JK—˜8‹@2ÆàÇ•56¥Š£ƒ„`¥•ê<®Ègš`ɶJ]<€•Ê`HË9:;<´µ¶?]<^0Á2345¨
©#`•‚£ƒ„6G89:;<=>‹@INR@†Ì#0Á2345ÍdM†Î#¢£¤5KϦÁJ•€£45Ž6Ы`¾Ûº»\]<^
!"#$%&'()'*
•€¾¿1À
!+,-./0*
!1234*
*+,-.Case reports!1"#/-letterab’Ñz~•6G89:;<=>`F;:@0†Ò‡ˆÅJ78#@¢£¤5K6¥Õ”•€”KÓJ[Š`Ó¶?e•[*+\]<^
Carr ME, Klotz J, Bergeron M.
Coumadin resistance and the vitamin supplement "Noni".
Am J Hematol. 2004 Sep;77(1):103
15307118
h¹J=>‹AB4C5D6"®AMñG:Fì7@”®1K—˜8”6ñÔ9:;V;î“9êV;^“9@0Á2345Æ0†Ò‡ˆÅ67
89:;<Vì@”•€¾¿1À”‹—•V;aÛ`Õ
!1267*
!PMID*
!51*
!"#$%&'()'*
Z[ËA.AAà5@\Á]à5/
!+,-./0*
*+,-.1*+/
!1234*
^_•`a*`z{|}6¡_‘<Mbz{`†‡6cd‘<ed?c¹Vb@”J†‡cd6ˆ‰‘<[Š`0Á2345?8;ìê
<^ÝÞ‹@0Á23456fgç9¹789:;[`“îîIì7@¢£¤5K6h¹¥ÕZ[ËAJKÓ`abDà5áâÀDã?iWX9@
&j}k„‡*6»[9[*+J,-\]<^
6.5
(4.28)
!"#$% !1267*
Z[ËAKÓ8`warfarinJ˜8?l•b&j}k„‡*6m*9[^_•`a*J1+
noZ>@pq¦lõ@#órõ@sotu@vúwx@µyz@{¼o|}@oW~
z~-33.6/ Page525-528(2001.06)
!PMID*
6.6
(4.29)
!"#$%
6.7
(4.30)
!"#$%
!51*
Z[ËA`‹@žJ¶ÖWסJØÙS?Ú•Eê:;<”M?]<^=>‹žJ*ŠJÛÜ6ÝŠ@]<;‹EZ[FJÞß`–à9:
Z[ËA6†`‘<”M?ˆáEê<^0Á2345G8#J=>`‹@âãÆ¢£¤5K6h¹¥¦‘<¼½`H‘<ØÙ°±`@Z[Ë
A6KÓ‘<-`‹žJdM`¢£¤5K?¥¦Eê:;V;”M6›Ï‘<ܬ?]<^
!"#$%&'()'*
¼½¾¿1À
!+,-./0*
*+,-.1*+/
!1234*
0Á234578=>6Â<M»`‹@ÃÄ`789:;<®ÅÆÇÈÉÊ1£@ËÌÆÍÎJÏÐV…•\@ÑÒJ=>6ÓbÔÕÖ×
`ØÙ6ÚÛܬ?]<^ÝÞ@ßÒJ¬³`abDà5áâÀDã.TTã/?ä}9[1=>`Øå9@0Á2345æçG8J[Š`zè
é:;VéêëVìV;”M‹íî6Èï9[^
!1267*
Warfarin78=>JDà5áâÀD(TT)ãä}`ð‘<ñò6¥Š[1*+
#óôõ@ö÷ø@ùúkû@üýþÿ@ú!"#@$%&'
(ó)*+,"$-30.1/ Page47-50(1998.10)
!PMID*
!51*
ÝÞ‹0Á234560e12@Àâà34MJ_8`5;:ñò9[?@1+`‘67@Ý8“9:6;•:ÑÒJ<1À`][<”M?&
Ì\]<^•[@0Á234578=>`M•:«¬\]<¢£¤5K¥¦=‹>?)@ËA`‹B¹CDEê:Fì7@[MG7®©ªJ0Á2345M¢£¤5KJHIb6ÏÐ9:“ì•[M9:“@Jì7`KÓ9:9•Û´µ¶‹&;`]<^•[@L`MîìV;[Š`NO
?Œ9:P:V;=VJ`QR9:9•Û”M“]bG<^˺1‹SD`M•:i`HIbT¹UbVWV;“J\]<Xé`@YÒVËAM
®1MJK—˜8‹«¬\]<^
!"#$%&'()'*
&'()
!+,-./0*
*+,-.1*+/
!1234*
0123456789:;<=>?@AB4C5DE&'()F6G89:@012345HIJKLMNOPQRSJTUVWX6YZ9[
,-\]<^
!1267*
E&'()FME012345FMJ_8`abcdJefghi6Q9[1+
#jkl@mnlo
pqrYs&gtuvgwxyy$@40: p1-6, 2006
!PMID*
!51*
z{|}@z~•€•‚@zNƒ„V…†‡ˆ‰J[Š0123456789:;<=>‹Œ•Ž•`]<^•[AB4C5D6i8‘<’
“Œ•9:;<^”J•I@ˆ–9V;K—˜8J™š‘<›œ?c••:;<^01234578#J=>?AB4C5D6žŸ‘< ¡@
¢£¤5KJ¥¦6§¨‘<©ª?«¬\]<^•[@ˆ–9V;efghiJ™šJ-@®J¯˜8°±`AB4C5DJ_8?²³J
´µ¶\]<”M6·¸`€¹º»\]<^
7. !"=#H=ABIJKLMNOPQ3RI3SP
7.1
(3.1)
!"#$%&'(
JKLMIObservational studyP
!)*+,(
!"#$%&'()*+,$-./0123456789/-:*;<=>?@6K%&=AB/C)(DE'FG
!PMID(
Lubetsky A, Dekel-Stern E, Chetrit A, Lubin F, Halkin H.
Vitamin K intake and sensitivity to warfarin in patients consuming regular diets.
Thromb Haemost. 1999 Mar;81(3):396-9.
10102468
!-)(
!"#$%&'()*TUVWXY=+,=32%Z0250 µg/;[\=>?@6K%&/NO123456]^_`ab'()FG
!"#$%&'(
IJKLMP
!)*+,(
#Hcd=>?@6Kefg=%&0hiY>?@6KjklNm123456/N*TUV=no_e=pq_/C)(DE'FG
!)*./(
7.2
(3.3)
!)*./(
!PMID(
!-)(
!"#$%&'(
!)*+,(
7.3
!)*./(
(3.4)
!PMID(
!-)(
Khan T, Wynne H, Wood P, Torrance A, Hankey C, Avery P, Kesteven P, Kamali F.
Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin.
Br J Haematol. 2004 Feb;124(3):348-54.
14717783
•w9=>?@6K$rs:*teZ0TUVu=ƒ„$•…'123456X}=v‘_$’z*G
IJKLMP
TUVu=€vw†+,=>?@6K%&9e123456no_e=p“/C)(DE'FG
Sconce E, Khan T, Mason J, Noble F, Wynne H, Kamali F.
Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of
anticoagulation.
Thromb Haemost. 2005 May;93(5):872-5.
15886802
>?@6K$;<rs:*teZTUVu$vwxy*Fz={|}~•O0TUV=€vw_/-:*#H•‚=>?@6K%&9=ƒ
„=ABZ…†)e‡ˆd‰*G'c'0Š‹t=Œu_/C)(Zxd†*•Ž`78~•*G
rstu#$)*+,$K-./01
67-+¡äs#ØäCH¿IJ
1. ÀÁ-8±½¾C1DE1FG
!"#$%&'(
!)*+,(
Eš›œ•G
rstu#$®1]-^_cKLiMN]*+,$KOPQRMS‹ŒiwQˆ-TUiÀÁ-8±½¾-Ö$
Homma K, Wakana N, Suzuki Y, Nukui M, Daimatsu T, Tanaka E, Tanaka K, Koga Y, Nakajima Y, Nakazawa H.
1
!)*./(
!PMID(
!-)(
Treatment of natto, a fermented soybean preparation, to prevent excessive plasma vitamin K concentrations in
patients taking warfarin.
J Nutr Sci Vitaminol (Tokyo). 2006 Oct;52(5):297-301
17190098
ÀÁMVe5‹)2g{UBacillus subtiliscWXP:•-ÀÁ•;•2¦wUy23ï‘kPQMN]*+,$KOPcYZef5Rb{
U:rstu#$®1^_2¦wUy:ö[01iP2VeQÀÁM;D5‹)cef5HyP€iwR
2. *+,$K-ÂÃÄ2xwUC1DE1FG
2
*ÅÆÇÈÉ•5HÊE1970Å˘vÌÍ45iÎRŠµŸÏw67v:ÐÑÒ2Ó•5’“ÒyŠ5QˆG
!"#$%&'(
!)*+,(
Eš›œ•G
XYZ…†-‘kÒ23¨PQ*+,$K-<=)>äHI-ÂÃ
Udall JA.
!)*./(
Human sources and absorption of vitamin K in relation to anticoagulation stability.
JAMA. 1965 Oct 11;194(2):127-9.
!PMID(
!-)(
5897315
?©@A2g5*+,$KBC22D;<–—-*+,$Kv:¦•Iß>ä2¦•5*+,$KÂÃ-àfiEFMGhR
3. Ü‘kiINR2¯45í1l*+,$K-ÝÃ*qE+1-ö*ÒGC3DE3FG
!-)(
˜™fÔÕÖ!×ØÙ@Ú@œ•Eprospective open label crossover studyG
VWXYZÛeINRcÜ‘ki^_2¯45*+,$KÝÃ-˜™f¤¥
Ford SK, Misita CP, Shilliday BB, Malone RM, Moore CG, Moll S.
Prospective study of supplemental vitamin K therapy in patients on oral anticoagulants with unstable international
normalized.
J Thromb Thrombolysis, 24, 23-27, 2007
17323135
*+,$KMÝÃ45‹)v:ýß-^_eINR-úûcãî45HyP€iwc:þi5àÿ!Hx"#2~Q5Ö$cžNeŠ5Rðœ
•-pqv:•-ghiœ•-%&¡$M'(@ä45y-eŠ)hR
!"#$%&'(
,0-.‰ÕÖ/£012345œ•Edouble-blinded, randomized, placebo-controlled parallel design studyG
!)*+,(
rstu#$67Ò289Ü}-úûcŠ5^_2¯P:*+,$K-VWïÝÃvXYZ“-‘kÒM:;45‹)cef5
!"#$%&'(
!)*+,(
3.1
!)*./(
!PMID(
3.2
3.3
!PMID(
Sconce E, Avery P, Wynne H, Kamali F.
Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in
response to warfarin.
Blood. 2007 Mar 15;109(6):2419-23
17110451
!-)(
*+,$KMÝÃ45‹)v:‘kPQXYZ“MÞ5¶•eiß:rstu#$\¾2g5‰àiá01-âŽMãI4)¿TI€5R
!"#$%&'(
!)*+,(
§ä×Øå!æçèéêERetrospective analysisG
XYZë$ä×@sMìˆ5í1l-*+,$K•‚
Reese AM, Farnett LE, Lyons RM, Patel B, Morgan L, Bussey HI.
!)*./(
Low-dose vitamin K to augment anticoagulation control.
Pharmacotherapy 25: 1746-1751, 2005
!PMID(
16305294
ƒ„:îl-*+,$KMVWï2ÝÃ45‹)v:ð¤¥-^_2¦wU:[\ñò©2¼{QINRó)¼{Uw5ôõMö÷2øSŒ
ù:INR-úûMíüŒùQR
!)*./(
!-)(
4. !"#$%&'()*+,$K1)-./0123456789):;<=>?@-ABC1DE1FG
!"#$%&'(
6789ELiterature reviewG:=>?@-AB
!)*+,(
!"#$%&'();<HI-*+,$K1)-./01234567EJKFLGMNOPQRSTU:VWXYZ[\]-^_2;<`
'M45a\b<_cd1ef5ghi:jkl-*+,$KMmn;<MoPQR
Booth SL, Charnley JM, Sadowski JA, Saltzman E, Bovill EG, Cushman M.
!)*./(
Dietary vitamin K1 and stability of oral anticoagulation: proposal of a diet with constant vitamin K1 content.
Thromb Haemost. 1997 Mar;77(3):504-9.
!PMID(
9066002
!-)(
6789-pq:*+,$K)rstu#$-./01-FLv:wxy;z]-*+,$Kml2g{U|}ef5)wh~•eviwHy
P€iwRPHP:;<HIjkl-*+,$K•‚vƒ„-*+,$K…†M‡xQˆ2‰NeŠ5‹)coŒ€QR•PU:Ž•-RDA2
.•45ghi‘kPQ*+,$K1•‚c’“i;<=>?@MFLPQR”•:;<–—-*+,$K1)rstu#$)-./01M}IH
245Qˆ-˜™fš›œ•cžNeŠŸ:‹‹eFLPQ;<- ¡¢£¡$v•-ghi¤¥2¦wUd1Œ€5HyP€iwR
4
5. rstu#$®1]-^_2¯45:;<-°±E²2*+,$KG2xwU-³|C1DE1FG
5
!"#$%&'(
!)*+,(
§*?@E*+,$K)rstu#$23¨PQ©ª-«¬-G
rstu#$®1]-^_2¯45:;<-°±E²2*+,$KG2xwU-³|
Booth SL, Centurelli MA.
!)*./(
Vitamin K: a practical guide to the dietary management of patients on warfarin.
Nutr Rev. 1999 Sep;57(9 Pt 1):288-96.
!PMID(
10568341
rstu#$-XYZ012¯45*+,$K-1l013´v:µ¶·¸Œ€Uwiw-e:Ž•-RDAeŠ565-80 µg/ƒM¹Q4g
hijkl-*+,$KM•‚45‹)v:rstu#$®1]-^_2¯P:ºy»•¼€’“i½¾)¿TI€5R
!-)(
6. Ã*BAsf@át01^¸2³´…w>%&'()*>9<\ñ79þÿ”OuR2êë p1qr1`s
!"#$%&'(
êë
!)*+,(
vw5x-yC•³´…w-NnKz#^ʼn5{|}~8Oh5•;}~8934950%5:;89349€15%-³´…wKF
G<^¸2>9`T-U2•>{|5}~k>9<\ñ7O•2³´•‚Oظ^5NOR2ST-U2V%&'()*>DBE*K9<\ñ
7•ƒ€Ñ|1^ʼn5+,8tu•FGK„o2•>-…W<¸>01^¸2V<{<5•1|9…wŒ-OhDBE*KKÏHOÐ.³´
…w-†w<^¸2’“”-U‰55xOêëR2ST-U2Vk‡5Ã*BAsf@Cˆ:’“•³´…wONn<5%&'()*>9<
\ñ79þÿ”Oظ^êë<=V
6
Ã*BAsf@át01^¸2³´…w>%&'()*>9<\ñ79þÿ”OuR2êë
(N8²)
!)*./(
‰ÏŠ‹5Œ¨‘š
N°>k°h51i2j Page343-345(2004.02)
!PMID(
!-)(
³´…w98O•(gÁ)ö*(+,*(tu*•È5DBE*K-Ï€ÐW12•>-Ñ|1^¸2h9Œ-Oh5Ï€9vw98ODBE*KÐW1^¸2•>-–|{>•‚=VW=5Ù1|9vwO•DBE*KKÏHOÐ.h9hU‚=V•1•‰5%&'()*6734•5/w
012C•€5™x34K5xOê65{Ø5N78k97O:;O<=<=IC5³´…wK>7R2•>-STCU2>?@12V
7. %A'()*6734OÅ22DBE*KÐbv99+,AB p1qr1`s
!"#$%&'(
CD
EFgG)*HIJKk9%&'()*i)j]r%A'()*®sK678934C•5DBE*KLMFGO•‰%A'()*®9lŽKøù
!)*+,(
0ú2=#5NO-STCU2V<{<5%A'()*®9lŽOPQRDBE*K9FGH9mnOظ^5–R•ASK4<=`T••
¸VÙ•C5UV_`K#O5%A'()*®>TPNrtotal parenteral nutirtion; 8WXYXYs7Z‡DBE*9Å•ÆE[XY9>9
<\ñ7K5mn9]•¸^Ox_<=V
7
%A'()*6734OÅ22DBE*KÐbv99+,AB
(N8²)
!)*./(
`a–¢58b¬–5c¨de
NkîfAg&h39i7j Page2072-2079(2003.07)
!PMID(
!-)(
kl5mØ9n§><^5%A'()*®6734OTPN7Z‡DBE*9Å•ÆE[XY9KopR2ì•5•9x_3K>7R2•>K
Pq<5W=Šr<=¸V
8. tuvw89DBE*K9xyp1qr1`s
!"#$%&'(
êë
!)*+,(
³´…w><^µ¶-·¸tuvw8O•5¹º><^»A&5¼½¾¿5ÀÁÂÃÄÅ•ÆÇ¿•ÈÉÊ9˸ÌÍCU‰5•1|O•
ÎODBE*K-Ï€ÐW12•>-Ñ|1^¸2V<{<5³´…w><^ÒÓ01=ÔÕ•Ö×9tuvw89DBE*KOظ^•5Ù9
ÐbÚו–|{O•‚^Å|Û5vw9ÜÝOhDBE*KÐbH•Þß01^¸•¸•>-ϸVÙ•C5àá01^¸2âãäåæÅ•
Æçè9tuvwOظ^5DBE*K9xyKé¸5ÐbÚ×Kêë<5Ù9•Ž{|Úì91ˆM=‰FGH9Š‹Ké‚=VW=5¤
íîïAðOظ^hxyKé‚=V
tuvw89DBE*K9xy
8
(N8²)
!)*./(
—˜ ™š , 8› œ• , žŸ ¡¢ , £¤ ¥¦ , §¨ ©• , ª« ¬…w®¯°±² 47(2), 85-88, 2006
!PMID(
!-)(
z^9tuvw{|DBE*K1K}~<5K2•z€}~01•{‚=VW=5ƒ„tuvwKF…<=†‡51ˆM=‰20-380 µg9DBE
*K-FG012>Š‹01=VŒI9•Ž•‰5%A'()*6749†‡5tuvwFG-+k•‘OmnK,o2’“”-U2•>–|{>•‚=V
9. %&'()*i)j]9klOmnK,o2DBE*KFGHp1qr1`s
!"#$%&'(
!)*+,(
9
(N8²)
!)*./(
êë
%&'()*ñ7OmnK,o2DBE*KFGH5klKòó•¸DBE*KÐH9ôAõAöÃ*9b÷Oظ^V
%&'()*9lŽKøù0ú2DBE*KHû‹9üý•þÿK!"=#5À$B)*%>&'êëKé‚=V
%&'()*i)j]9klOmnK,o2DBE*KFGH
!"#$
Nutrition Support Journal, 5(2), p20-22, 2004
!PMID(
!-)(
%&'()*+,-./012345%&'()*678934-:;<=>?5@AB&C9DBE*KFGH9IJKLMNOPQR2S
T-U2VW=5XYZ[A@\A]><^_`Kab<534O_`K'cAdefgR2SThU2V
"#$%&'()*+'K,xyZ.
234k)*+'KP1Q:)*+'K@2AB(,xyZ.o
Ú"#$%&'()*+'K,xyZ./ÛÜ1Ým56/ÞQßà
!"#$%&'()*+'K,-./01234,56,789:;"#$%&'<.=>?)*+'K@
2ABCDEFGABHIJK/LMNOP1Q:RSTUV(/01WXYZ.,[\C]^_
P`;a/bc56Cdefg&eh/0156?ijk50l;mn305o;pqrsCturs/0
156:10lkmn95o_PvUw
!"#$%&',WXYZ./¡¢H£¤TU)*+'K@2AB,¥¦:;DEFG–kOsmolite;
Ensure;Ensure Plus;Isocal;Nutrilite 330;VK§¨DE–;$#©&ª«®;¬#*+'®;-®'
¯®'®•15l;mn115o;°±k14l;mn35;²³15:’´µ¶·¸¹o;••kº²›»¼;
½¾ª¿&e;ÀÁÂ-;Ã*f;ÄÅ;©¯gÆ;/»|»;©&$¯"e;Ç&e'Èef;«ÃÉ';•,
Ê•12l;mn95o;«¾Ã¯k4l;mn45o;)*+'K@2¬#Ë)*+'–k4l;mn25o;ÌÍ
«ÍÎ&k1l;mn15o;ÏÐk1l;mn15o;ÑÒ*Ó¿k1l;mn15o;ÎÔÕÖefk1l;mn
15o;’“AB,Í;'(Ì#©¾'k1l;mn15o;••ÕÖefk1l;mn15o;7×ØÙk1
l;mn15o_PvUw
!V›œ:a/bc56/01•,_;23Z.H{|U)*+'KLM‹:25-6000 µg/d,žŸ_
Žœ›Uw
!WXYz3,{|U}~•
€•‚ƒ„>…,56†T/;‡ˆ‰S_Š‹Œ•,UŽ/i‹,••LMHNOTUw
‘’“”•,UŽ/DEFG–,LMHNOTUw
—A{˜H™/[šTUw
!23Z.?{|Uá,¶âã(Tß;789?}~AB,LMRS/0`ä,WXYåæ/çèT
ßQUw
×ØtÙÚ’×Û@ÜÝÛ@Þßà“&áâã
äVWXYZ*å…æÚ.‚01@çèŸn='()*K+,Séê
!'()*K+,-b4&cdEJeUS2
-/0123456789:;<+=>2010?@A8II B&CDEFGKHIJKLMNOfF'()*K&ghiBjk.l>mn=&?op78&qr&sFG=Htu1@v9F?wI
Jop78P;xy_=&.z{J'()*K+,-;c|M51}w+,-;b4_=&B~#F
G•aH5€5@•.‚ƒ='()*K„…N†&‡ˆFG=op‰]ŠW‹Œ•WŽ••‘•ŠW•*
’ucOC“”•?@•–—M?˜™5$•š&›œ•žFG%@ucOC;]^Ÿ =$>.?@¡¢F7
8•ž&£QŽ.z{J-¤¥’‚‚¦§500 µg/"“;{_=¨MB©Ÿn10=H¨n`%@•š
&ª«.z{J'()*Kz{-?@o¬‰-ŠW‹Œ•WŽ®¯°¯*'*;‡ˆM_=±².³´
1µ0OPQBeUmn=H5€5@¶}J•&·¸9:;xy_=$>.@'()*K.`=••‘•
ŠW•*&¶¹º&ŠW‹Œ•WŽBz{€»a€?¼½NjFG=HŸm.@'()*K¾®Z¿*°
ÀÁ.`=•šÂÃÄ&ÅÆ.Ç_=¿(ÈÉZ••BÊËŸn10=B@45 mgM0aµ-&¿ÉŒ
Ì*ÀÁ.`=Í&FG=H¤¥`%@ÎÏEJgh9:;ÐÑFÒ=+,-’1 µg/kgÓÔ/"Õ—“
;Ö3-M_=¨MB}#FG=MeUmn=H
!"#$%&'()*+,$%-.
!1"#$%&'()*K+,-./012
345$6789:;<=$>.?@A80 µg/"&'()*K+,BCDEFG=H
"IEJ+,B50 µg/"KL.J=M@6789:BN34.J=OPQBG=H
RS@"IEJ'()*K+,-B250 µg/";TU=M@VWXYZ*[\QB]^_=$>@250
µg/"?TUJ0`a._=H
!'()*K+,&ëìí./012
'()*K+,&"î&”RïEJ”ëì?@100 µgðñ._´ÒFG%@250 µg/";TUJ0`a
._=’'()*KB100 µgòó_=M@INR?0.2]^_=M&ÊËG%“H$½5@¨&9:B3-4"
ôõöM@678÷Ø.øù;úû_OPQBG=H
1000 µgÕ—&”…-&'()*K+,?@üÐ+,FGu1Íу=´ÒFG=H
RS@'()*Ý.ýþŸn10=`aJ25 µgÕ—&Æ-&'()*KFGu1Í@ÿ&+,B!"G
=0?‰#Ÿn$9:B2$ôöm0õöM@678P.øù;úû_OPQBG=H$½5@"IE
.'()*K+,-Bµ0æÚ.‚01?@øù&J0±²ÍG=H
ÿ51@"IE.'()*K&%&J'(&)*;+º_=½ƒFJö@'Ù€m&'()*K+,;R
4._=¨MBÔ{FG=H
!6789:BN34JæÚ.,5---2
.I/mn10=`aJN34Q&0•BJ0&.@INRBëì_=æÚ.,51?@"IE.100150 µgÕ—&'()*K;12_=M@VWXYZ*&ò-;3aB@6789:B34_=OPQB
G=H¨n?@R4-&'()*K;12_=¨M.`%@"î&'()*K+,-&ëìBÅ=Ù.`=
MeUmn10=HINR&ëì&c|M51@45667¤8.INRB3Ð÷Ø9:.J=@G=0?V
WXYZ*&…-ë;BÆJöMÍ3Ðz{½u$@G=0?INR&SD>0.5&$>.VWXYZ*…ë;BÆJöMÍ3Ðz{.J=±²FG=H$½5@'()*K+,!"ñ&1-2$ô?@INRB<.
]^_=OPQBG=&F@=>JVWXYZ*…-?@Mop78PABBz{FG=H
!"#$%&'()*+,-./0,123456789:8;<=>?8@<AB8CDEFGHIJK
'KLM,600 µg/100 gNOPQ34RSTQUVWXYZST[7\]^_`aSTQU
!"#$%&'()*+bc278YZMbde,fgh345678i567FjX1khlmno,
pqrsQU
tuvwxXy8:z8{|A'}8~•8€•o8br8‚<ƒ„&…8†‡ˆ‰Š8‹'Œ'•>8
‡ˆ‰Š8cŽr8•v2•q•8‘oEFGHIJK'KLM,50-340 µg/100 gX34R
’“”19•–—˜™!š›œ•žŸX gE¡¢£¤¥R1¦820§FGbc.QnoXYZMH8
“¨290.1 gST¦8©Xª«H8lmno,97.7 g8©sF¬,192.4 gST[/U-/8IJK'
KYZMH8®¯S235 µg/°±[/U5²³S8˜™°´21SH8noYZMXµ¶·H1°350
gFG5672QU²s1¦8"#$%&'()*+X1°XIJK'KYZMH8¸¹E235 µg/°RX
º»¼Fjb½PQ58¾¿ÀÁÂhIJK'KYZMEº80 µgRbÃ_Q5ÄPrsQUÅ[78ih
IJK'KXÆÇÈSTQlmnoH8¸¹Xº»¼E50 gRXYZb_Q1kbÉÊ.8Ë̼X
300 gXnoHÍXnoSÎk1kb_Q5Ï2U
-Ð/1kh()0ÑNÒÓ672QÔÕT¦Öw×ØÙr8ÚÛ!ÜÝÞb1Qß0àá!26â"#
$%&'ãäbc.Qß0àáâåÜ戅ç#844(3)8p. 967(171)-p. 975(179)82008!"#$%&'()*+bc278YZXde,T-¦h2345678èé8Ÿêé8ëé8‡ì„é8
íé8îïEðñb1[7H10 µgòóT¦R8ôï8tu8A'„'8õ|;<„ö8J÷øù8õ÷õ8ú
û8wx8/.X²8ü¿k8ýþEFGHIJK'KLM,5 µg/100 gFjX34RSTQU
°"#$%&'[<=>'K;±²‰),³a/0?\B´µ3¶·;••¸¹
!"#$%&'()*+,-./01234567189:;<=>'K;[email protected]
JK,LM0N;OPQR,STUVWXYZ[I\]^_GH`a^a0N;bcIdebc,fg
hi;jkh0lm,Ln/op;qrs<=>'KCDt3CDuvIwx_0*+,LM&yzVq
rH<=>'KCDtI{|h}BH~•€jGH`e•‚0ƒ„^]…†,<=>'KCDtj‡B.
*+I0‡t;<=>'KCD_Gn/i{|Bˆp‰),BH`a^a0GHŠ‹t;<=>'KVŒƒ
CDa/.H*+_G•‚0‡t;<=>'K;Ž€CDI{|B••,B]B.^ia•B.`‘s0
lm,Ln/I”’‹as“”•–—V˜™YHsš,I012^];<=>'K;CDVŠ‹,YH
Z[j›œ_GH”[.•ž•Ÿj ¡¢•/.H,i^^£]¤0"#$%&'()*+,¥a0¦§
¨©ª,fg.s’«Bƒx;<=>'KCDtV¬-a/.HbcI®¯B^ns`
!lm,Ln/0<=>'KCDtj1ƒµ[a/º»¢•/.sM0¼½;12,¾•/<=>'K¿ˆ
1836718VCDa/.HÀÁ0‘sÂÃa/CDa/.HÀÁB¯jGM0ˆp‰);ÄZHÅ
ÆB<=>'KCDt;¶·jÇÈ_GH`
!ÏÐÑ,$
Ò'(´&MNOAK9ÓWVÔ
ÏÐÑ,„ÕÖ(c-'×&ØÙÚÇ3ÛZWÕÖ(&ÜÇ03\FDE]5ÝÞÂßàeá5âãäå
 æçèéêë'(ìíîïðÂñŸòóôòóõöóö÷øùÑú*ûïòù\üýþ]
!"#$
1MNOAKL5"#&´••5%9&'("#•€a5·@)i*5DEUq+5l@,2±35-.#5
/05¯1\160-640 µg/100 g]9235[#5áÏ)®4&(\160-340 µg/100 g]9_`ST
UVWaY\5/5[#5áÏ5®4&49L5MNOAKPQRSTUVWXWY]
1¶ÿE5—W‚q5áÏ5F!PW•5"ÓTW•5[#5Uq‚q5ƒ$&‚5ƒT§}5•À•L5MNO
AKS-P•XW\4 µg/100 gœ•]Y
!%&'()*+,$
1rs5ts5uvs5kw2s5xys\z&{|5EX}&~•5€•85XT‚&‚&•ƒ5E9„
17-40 µg…†S‡]L5QRMNOAKˆSTXWY‰Š)‹3Œd•Ž&Š•(9MNOAKL•X
`5‘3’s•10 µg/100 g“”•€aY
1‰–\10 µg/100 g“”5ƒ—Z˜™9L16-24 µg/100 gSš])›–\5 µg/100 gœ•]&ž
Ÿ 9MNOAKL•XWP5¡–L¢£¤MNOAKˆ_`Sš\¥¦5š§5••&¨©~–•38-70
µg/100 g]Y
1ª˜s\100 g«ƒ¬&MNOAKS-]cZV5®¯ª\210 µg]cXƒ§ª\120 µg]L¢£¤_
`5°±3lª\42 µg]5H²[ª\36 µg]5³vª\29 µg]L´…†5µT•¬ª\11 µg]5¶Tª
c•?·@2¸ª\5 µg]5¹3ºªc»¼½ª\4 µg]5)Zª\¾-]L¿WY
À3Á±AL53-71µg5ÃN3L17-30µgSšYÄ*.&Å5ÆÇÈaª9ÉÊVMNOAKSPËTaÌÍ΀¬Y
1¹@±)Ã<d&AB,9•MNOAKLCD9STUVaP\EUFU5G100 g«ƒ¬MNOAKˆ
1300c820 µgS‡]5HI&ÆÇ-•LJEK`LM9XKXW—NEY
!-,$
1Zb-,cZV5M3d5ef5gh5?ijk35lmAn35opf9L5MNOAKPDcqRST
UVWXWY
1234352265789:;5<=5>=5?3@A=5B=5C=5DEF=5GH=&IJK9
L5MNOAKPQRSTUVWXWYZ[Z5:;\4000 µg/100 g]5^=\2900 µg/100 g]5<
=\1400 µg/100 g]5>=\1500 µg/100 g]&=9L5MNOAKP_`STUVWaY
!*./0$
1MNOAKL56•a57È589TƒL:å;A<=.Ž&*.09ÉÊVQR>?ZXWY